ACADIA Pharmaceuticals Inc.

ACAD · NASDAQ

ACAD is no longer the kind of biotech where everything hangs on a single trial. The sharper question is whether NUPLAZID and DAYBUE can fund a third CNS franchise before concentration, payer pressure, and pipeline risk catch up.

Follow Add to Watchlist Ask Question

NASDAQ ACAD Coverage Bootstrap Biopharma Neurology Rare Disease

Latest ReportMay 13, 2026ACADIA (ACAD): two drugs, $1.25 billion guidance, and one Alzheimer readout that can change the stockView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.